Andrew W Roberts1, Brendan Saloner1, Stacie B Dusetzina1. 1. Dr. Roberts is with the Department of Preventive Medicine and Public Health and the Department of Anesthesiology, University of Kansas Medical Center, Kansas City. Dr. Saloner is with the Department of Health Policy and Management and the Department of Mental Health, Bloomberg School of Public Health, Johns Hopkins University, Baltimore. Dr. Dusetzina is with the Department of Health Policy, Vanderbilt University Medical Center, Nashville, Tennessee.
Abstract
OBJECTIVE: This study examined buprenorphine prescription uptake and expenditure trends among privately insured adults from 2003 to 2015 to inform efforts to expand opioid use disorder treatment. METHODS: A study with a repeated cross-sectional design using MarketScan prescription claims data was conducted to describe trends in total and new buprenorphine use and median total, plan, and out-of-pocket expenditures for a 30-day buprenorphine prescription among privately insured adults from 2003 to 2015. RESULTS: New and total buprenorphine users increased dramatically from 2003 to 2013 and plateaued. Total buprenorphine spending was stable from 2003 to 2008, increased from 2009 to 2013, and declined from 2013 to 2015. Out-of-pocket expenditures steadily decreased from $67 in 2003 to $32 in 2015 for a 30-day prescription. CONCLUSIONS: Buprenorphine treatment costs were stable for health plans and declined for privately insured adults since 2003. Identifying remaining barriers to addressing the opioid addiction treatment gap is a priority.
OBJECTIVE: This study examined buprenorphine prescription uptake and expenditure trends among privately insured adults from 2003 to 2015 to inform efforts to expand opioid use disorder treatment. METHODS: A study with a repeated cross-sectional design using MarketScan prescription claims data was conducted to describe trends in total and new buprenorphine use and median total, plan, and out-of-pocket expenditures for a 30-day buprenorphine prescription among privately insured adults from 2003 to 2015. RESULTS: New and total buprenorphine users increased dramatically from 2003 to 2013 and plateaued. Total buprenorphine spending was stable from 2003 to 2008, increased from 2009 to 2013, and declined from 2013 to 2015. Out-of-pocket expenditures steadily decreased from $67 in 2003 to $32 in 2015 for a 30-day prescription. CONCLUSIONS:Buprenorphine treatment costs were stable for health plans and declined for privately insured adults since 2003. Identifying remaining barriers to addressing the opioid addiction treatment gap is a priority.
Entities:
Keywords:
Addiction; Buprenorphine; Cost of care; Medication assisted treatment; Opioid use disorder; Prescription coverage
Authors: Christopher M Jones; Melinda Campopiano; Grant Baldwin; Elinore McCance-Katz Journal: Am J Public Health Date: 2015-06-11 Impact factor: 9.308
Authors: Tulshi D Saha; Bradley T Kerridge; Risë B Goldstein; S Patricia Chou; Haitao Zhang; Jeesun Jung; Roger P Pickering; W June Ruan; Sharon M Smith; Boji Huang; Deborah S Hasin; Bridget F Grant Journal: J Clin Psychiatry Date: 2016-06 Impact factor: 4.384
Authors: Alex K Gertner; Allison G Robertson; Hendree Jones; Byron J Powell; Pam Silberman; Marisa E Domino Journal: Health Serv Res Date: 2020-03-12 Impact factor: 3.402
Authors: Tae Woo Park; Marc R Larochelle; Richard Saitz; Na Wang; Dana Bernson; Alexander Y Walley Journal: Addiction Date: 2020-01-20 Impact factor: 6.526
Authors: Jake R Morgan; Emily K Quinn; Christine E Chaisson; Elizabeth Ciemins; Nikita Stempniewicz; Laura F White; Benjamin P Linas; Alexander Y Walley; Marc R LaRochelle Journal: Med Care Date: 2022-03-01 Impact factor: 3.178
Authors: Kathryn E McCollister; Jared A Leff; Xuan Yang; Joshua D Lee; Edward V Nunes; Patricia Novo; John Rotrosen; Bruce R Schackman; Sean M Murphy Journal: Am J Manag Care Date: 2018-11 Impact factor: 2.229
Authors: Julie M Donohue; Marian P Jarlenski; Joo Yeon Kim; Lu Tang; Katherine Ahrens; Lindsay Allen; Anna Austin; Andrew J Barnes; Marguerite Burns; Chung-Chou H Chang; Sarah Clark; Evan Cole; Dushka Crane; Peter Cunningham; David Idala; Stefanie Junker; Paul Lanier; Rachel Mauk; Mary Joan McDuffie; Shamis Mohamoud; Nathan Pauly; Logan Sheets; Jeffery Talbert; Kara Zivin; Adam J Gordon; Susan Kennedy Journal: JAMA Date: 2021-07-13 Impact factor: 56.272